LACTATE CLEARANCE AS A SURVIVAL PREDICTOR IN PATIENTS WITH HEMATOLOGIC DISEASES WITH SEPTIC SHOCK
Author(s): ,
Iurii Osipov
Affiliations:
Bone marrow transplantation department,Almazov National Medical Researche center,Saint - Petersburg,Russian Federation
,
Galina Salogub
Affiliations:
Bone marrow transplantation department,Almazov National Medical Researche center,Saint - Petersburg,Russian Federation
,
Vadim Bezrukikh
Affiliations:
Bone marrow transplantation department,Almazov National Medical Researche center,Saint - Petersburg,Russian Federation
,
Vladimir Ivanov
Affiliations:
Intensive care unit,Almazov National Medical Researche center,Saint - Petersburg,Russian Federation
,
Evgenii Mikhaylov
Affiliations:
Bone marrow transplantation department,Almazov National Medical Researche center,Saint - Petersburg,Russian Federation
,
Nadezda Shnalieva
Affiliations:
Bone marrow transplantation department,Almazov National Medical Researche center,Saint - Petersburg,Russian Federation
Natalia Stepanova
Affiliations:
Bone marrow transplantation department,Almazov National Medical Researche center,Saint - Petersburg,Russian Federation
EHA Library. Osipov I. Jun 15, 2019; 266895; PS1278
Mr. Iurii Osipov
Mr. Iurii Osipov
Contributions
Abstract

Abstract: PS1278

Type: Poster Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 17:30 - 19:00

Location: Poster area

Background

Infectious complications are one of the main causes of mortality in patients with hematological diseases. Neutropenia is common adverse effect of antitumor treatment. These patients have high risks of development severe infectious complications (sepsis and septic shock). It is known, that poor lactate clearance is associated with increased mortality in the general population of patient’s. We evaluated the prognostic value of lactate clearance in patients with neutropenia grade 4 (CTCAE v4.0)

Aims

To evaluate the clinical outcomes of septic shock treatment in patients with myelotoxic agranulocytosis depending on the clearance of lactate.

Methods
127 patients with septic shock were included (between July 2015 and December 2018). A prospective and retrospective diagnosis of septic shock was established on the basis of Sepsis 3 criteria: arterial hypotension in combination with an increase in lactate of more than 2.0 mmol / l.  The highest incidence of septic shock (up to 35%) was registered in high-risk group patients: during the induction remission of acute myeloid leukemia and recipients of allogeneic hematopoietic stem cells. 88 percent cases were associated with gram-negative bacteria (Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, Serratia spp. and E. coli). The median duration of neutropenia before the development of septic shock was 15.1 (13.26–17.06) and 17.72 (16.33–19.12) days in patients who died and survived (p=0.03, Log Rank). The levels of C-reactive protein and procalcitonin did not differ.

Results
The median lactate values at the time of diagnosis of septic shock in survivors and non-survivors patients were 2.9 (3.071 - 3.997) and 4.26 (3.665-4.867) mmol / l (p = 0.05, Log rank). 30 - day overall survival (OS) in patients with a lactate level of more than 4.0 mmol/l was 34%, with a lactate level of 2.0-4.0 mmol/l was 56% (p <0.001, Log Rank). All patients received serial lactate measurements were divided into lactate clearance >10% (n=26), >20% (n=46), and <10% (n=55) groups. Patients with a lactate clearance of more than 10% had higher 30-day OS (68% vs. 29%, p<0.01, Log Rank). The rate of lactate elimination (more than 10% versus more than 20%) did not have an additional effect on OS. In multivariate analysis with an additional assessment of the venous-to-arterial carbon dioxide tension, absolute lactate values, the prognostic value was shown only for the lactate clearance.

Conclusion
Achieving lactate clearance during the first 6 hours treatment septic shock more than 10% is associated with improved 30-day OS in patients with severe neutropenia. The advantage of this marker is an early assessment of the effectiveness of therapy. In the future, on the basis of lactate kinetics, it is possible to create the strategy of 'Early Goal-Directed Therapy'.

Session topic: 30. Infectious diseases

Keyword(s): Hematological malignancy, Infection, Sepsis

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies